Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CD38 | P28907 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91338 | 0.86 | P2RX7 (0.37) | TAAR1GAAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10290476 | 0.82 | MPO (0.40) | TAAR1GAAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2845042 | 0.82 | TAAR1 (0.36) | TAAR1GAAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5413856 | 0.80 | CYP3A4 (0.36) | TAAR1MEN1KMT2ASMN1; SMN2CYP3A4 | |
| SCHEMBL20326196 | 0.80 | CYP3A4 (0.39) | GAAMEN1KMT2ASMN1; SMN2CYP3A4 | |
| SCHEMBL9608978 | 0.80 | P2RX7 (0.41) | TAAR1MEN1KMT2ASMN1; SMN2CYP3A4 | |
| SCHEMBL19116110 | 0.78 | GAA (0.36) | TAAR1GAAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31152890 | 0.78 | CYP1A2 (0.33) | TAAR1KDM4E | |
| SCHEMBL23378582 | 0.77 | TAAR1 (0.36) | TAAR1GAAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6072587 | 0.77 | TAAR1 (0.41) | TAAR1GAAMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220131-A2 | PI3Kα INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-3008045-B1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | ANTABIO SAS (FR) | 2018-05-09 | — | — | EP | disclosed |
| US-9914712-B2 | Antibacterial thiazolecarboxylic acids | ANTABIO SAS (FR) | 2018-03-13 | — | — | US | disclosed |
| US-9914712-B2 | Antibacterial thiazolecarboxylic acids | ANTABIO SAS (FR) | 2018-03-13 | — | — | US | disclosed |
| EP-2884977-B1 | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9556168-B2 | N-alkylated indole and indazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160272601-A1 | Antibacterial Thiazolecarboxylic Acids | ANTABIO SAS (FR) | 2016-09-22 | — | — | US | disclosed |
| US-20150210687-A1 | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2015-07-30 | — | — | US | disclosed |
| US-20090253929-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| US-20080262037-A1 | Piperidine Derivatives for the Treatment of Chemokine Mediated Disease | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| EP-1824806-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006062476-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210687-A1 | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORC, RORA | TAAR1 804/4885GAA 1361/4885MEN1 2764/4885 |
| US-20160272601-A1 | Antibacterial Thiazolecarboxylic Acids | ME1, TALDO1, COASY | TAAR1 2080/4885GAA 26/4885MEN1 1657/4885 |
| US-20090253929-A1 | Chemical Compounds | CYP4B1, CYP3A4, CYP1A1 | TAAR1 912/4885GAA 1845/4885MEN1 104/4885 |
| US-20080262037-A1 | Piperidine Derivatives for the Treatment of Chemokine Mediated Disease | CCR3, CCR1, CCR4 | TAAR1 655/4885GAA 3863/4885MEN1 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.